At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 4 enrolled
Drug / intervention
[14C]-pamiparibdrug
Likely dose
[14C]-pamiparib 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Pamiparib Following Single Oral Dose Administration in Patients With Advanced and/or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating [14C]-pamiparib for Advanced Solid Tumors. Completed, enrolled 4 participants across 2 sites.
Detailed Summary
This is an open-label study, in participants with advanced and/or metastatic solid tumors, which consists of 2 parts: a research phase (inpatient) and a treatment phase. The research phase (Part 1) of the study will assess the disposition of a single oral dose of \[14C\]-pamiparib. In the treatment phase (Part 2) participants will be allowed to have continued access to pamiparib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartMay 2019
First PostedJun 2019
Primary CompletionOct 2019
Study CompletionAug 2020
TodayJul 2026
First PostedJun 19, 2019
Enrollment StartMay 29, 2019
Primary CompletionOct 21, 2019
Study CompletionAug 5, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.0 years ago
Interventions
[14C]-pamiparibdrug
During the treatment phase, pamiparib 60 mg administered orally twice daily